Stock analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) to post earnings of $ 0.31 per share for the current fiscal quarter, Zacks reports. Two analysts provided earnings estimates for Ironwood Pharmaceuticals, with the lower EPS estimate being $ 0.28 and the higher estimate being $ 0.36. Ironwood Pharmaceuticals reported earnings of $ 0.36 per share for the same quarter last year, suggesting a negative year-over-year growth rate of 13.9%. The company is expected to release its next results on Wednesday, February 16.
On average, analysts expect Ironwood Pharmaceuticals to report annual earnings of $ 1.29 per share for the current fiscal year. For the next fiscal year, analysts expect the company to report earnings of $ 1.46 per share, with EPS estimates ranging from $ 1.25 to $ 1.69. Zacks’ earnings per share calculations are an average based on a survey of research analysts who provide coverage for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ: IRWD) last released its results on Thursday, November 4. The biotech company reported $ 0.33 of BPA for the quarter, beating analyst consensus estimates of $ 0.31 by $ 0.02. Ironwood Pharmaceuticals had a net margin of 128.30% and a return on equity of 64.78%. The company posted revenue of $ 103.75 million for the quarter, compared to analysts’ expectations of $ 105.27 million. During the same period of the previous year, the company posted earnings per share of $ 0.23. The company’s revenue for the quarter increased 0.3% from the same quarter last year.
IRWD has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “conservation” rating and set a price target of $ 14.00 for the company in a research note on Monday 8 November. TheStreet downgraded Ironwood Pharmaceuticals shares from a “b-” rating to a “c” rating in a research note on Wednesday, December 8. Finally, Morgan Stanley raised its price target for Ironwood Pharmaceuticals shares from $ 13.00 to $ 14.00 and gave the stock an “equal weight” rating in a Tuesday October 12th research note. .
NASDAQ IRWD shares traded up $ 0.24 during trading on Friday, reaching $ 11.87. 2,288,449 shares were traded, for an average volume of 1,973,893. The company’s 50-day moving average price is $ 12.00 and its 200-day moving average price is $ 12.55. Ironwood Pharmaceuticals has a twelve month low of $ 8.78 and a twelve month high of $ 14.27. The company has a quick ratio of 4.77, a current ratio of 4.77, and a debt ratio of 0.57. The company has a market cap of $ 1.94 billion, a price-to-earnings ratio of 3.65, and a beta of 1.24.
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 52,644 shares of the company in a trade on Tuesday, November 23. The shares were sold at an average price of $ 11.58, for a total trade of $ 609,617.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Additionally, CEO Thomas A. Mccourt sold 46,327 shares of the company in a transaction dated Wednesday, December 22. The stock was sold at an average price of $ 11.41, for a total trade of $ 528,591.07. Disclosure of this sale can be found here. During the last quarter, insiders sold 168,402 shares of the company valued at $ 1,928,520. 12.60% of the capital is held by insiders.
Several institutional investors have recently increased or reduced their stakes in the company. Profund Advisors LLC increased its position in shares of Ironwood Pharmaceuticals by 5.0% in the second quarter. Profund Advisors LLC now owns 16,154 shares of the biotech company valued at $ 208,000 after acquiring 762 additional shares in the last quarter. CWM Advisors LLC increased its position in shares of Ironwood Pharmaceuticals by 3.1% in the second quarter. CWM Advisors LLC now owns 29,238 shares of the biotech company valued at $ 376,000 after acquiring 886 additional shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Ironwood Pharmaceuticals by 1.6% during the second quarter. Cubist Systematic Strategies LLC now owns 78,634 shares of the biotech company valued at $ 1,012,000 after acquiring an additional 1,205 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Ironwood Pharmaceuticals by 2.9% during the second quarter. ProShare Advisors LLC now owns 66,791 shares of the biotech company valued at $ 860,000 after acquiring an additional 1,875 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its position in shares of Ironwood Pharmaceuticals by 7.0% during the second quarter. Handelsbanken Fonder AB now owns 28,955 shares of the biotech company valued at $ 373,000 after acquiring an additional 1,900 shares in the last quarter.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a healthcare company, focused on the development and commercialization of gastrointestinal (GI) product opportunities in areas of high need, leveraging expertise and abilities demonstrated in gastrointestinal diseases. Its products include linaclotide, a type C guanylate cyclase agonist that treats irritable bowel syndrome patients with constipation and chronic constipation.
Recommended story: what are municipal bonds?
Get a Free Copy of Zacks’ Research Report on Ironwood Pharmaceuticals (IRWD)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Ironwood Pharmaceuticals now?
Before you consider Ironwood Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly asking their clients to buy now before the wider market takes hold … and Ironwood Pharmaceuticals was not on the list.
While Ironwood Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here